Chemoprevention of HCC With Statins, Aspirin and Metformin Chemoprevention of HCC With Statins, Aspirin and Metformin
A new meta-analysis examines the question of whether statins, aspirin and metformin are chemoprotective against the development of hepatocellular carcinoma.Alimentary Pharmacology & Therapeutics (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 28, 2023 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news
AAD: Risk for Skin Cancer Higher for Adults With Atopic Dermatitis
MONDAY, March 27, 2023 -- Adults with atopic dermatitis (AD) have an increased risk for developing melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC), with significantly higher risks seen for moderate-to-severe versus mild AD,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 27, 2023 Category: Pharmaceuticals Source Type: news
CRT Regimen Boosts Complete Response Rate in Unresectable Vulvar Cancer
(MedPage Today) -- TAMPA, Fla. -- More than 70% of patients with unresectable, locally advanced vulvar carcinoma had complete responses to chemoradiation with intensity-modulated radiation therapy (IMRT), according to a prospective study reported... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 27, 2023 Category: Hematology Source Type: news
Incyte gets FDA approval for new drug to treat rare form of skin cancer
Incyte's newly approved drug targets advanced Merkel cell carcinoma, a condition that afflicts fewer than one out of 100,00 people. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 23, 2023 Category: Health Management Authors: John George Source Type: news
FDA Approves New Merkel Cell Carcinoma Drug Zynyz FDA Approves New Merkel Cell Carcinoma Drug Zynyz
The PD-1 inhibitor received accelerated approval for adults with metastatic or recurrent locally advanced Merkel cell carcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 22, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Zynyz (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 22, 2023-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz™ (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 22, 2023 Category: Drugs & Pharmacology Source Type: news
FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma
On March 22, 2023, the Food and Drug Administration granted accelerated approval to retifanlimab-dlwr (Zynyz, Incyte Corporation) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 22, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA OKs Another PD-1 Inhibitor for Merkel Cell Carcinoma
(MedPage Today) -- Credit: Klaus D. Peter, Wiehl, Germany
The second time proved to be the charm for the PD-1 inhibitor retifanlimab (Zynyz), as the FDA approved the drug for Merkel cell carcinoma (MCC).
The agency had previously rejected... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 22, 2023 Category: American Health Source Type: news
Improved OS With Hyperfractionated RT in Recurrent Nasopharyngeal Carcinoma
(MedPage Today) -- Compared with standard fractionation, hyperfractionated intensity-modulated radiotherapy (IMRT) could significantly increase overall survival (OS), as well as reduce the rate of severe late complications in patients with locally... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 21, 2023 Category: Hematology Source Type: news
NHS launches new initiative to check for cancer in high-risk communities
A new initiative to deliver on-the-spot liver scans to check for cancer in high-risk communities has been rolled out as part of a major NHS drive to catch more cancers earlier and save lives. The programme identifies those at risk of the most common form of liver cancer, hepatocellular carcinoma, which makes up 85% of... Read moreThe post NHS launches new initiative to check for cancer in high-risk communities appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - March 15, 2023 Category: Nursing Authors: Wiliam Hunter Tags: Latest news Source Type: news
Active Surveillance for Papillary Thyroid Cancer Active Surveillance for Papillary Thyroid Cancer
Drs Ho and Sacks discuss key aspects, patient selection, and future modalities of active surveillance in early-stage papillary thyroid carcinoma.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 14, 2023 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape | Science Signaling
Antitumor immunity against liver cancer is impaired by SUMOylation of intracellular IL-33. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - March 14, 2023 Category: Science Source Type: news
Novel PET Imaging Agent Accurately IDs Clear Cell Renal Cancers
(MedPage Today) -- An investigational PET imaging agent -- zirconium-89 (89Zr)-deferoxamine (DFO)-girentuximab -- identified clear cell renal cell carcinoma (ccRCC) with high sensitivity and specificity, according to results from the phase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 13, 2023 Category: Hematology Source Type: news
Benefits Persist for Lenvatinib, Pembrolizumab in Renal Cell Cancer
MONDAY, March 13, 2023 -- For patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study published in the March issue of The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 13, 2023 Category: Pharmaceuticals Source Type: news
Key Abstracts in Renal Cell Carcinoma From ASCO GU 2023 Key Abstracts in Renal Cell Carcinoma From ASCO GU 2023
Key data in renal cell carcinoma from ASCO GU 2023 include phase 3 results on girentuximab and updates of CheckMate 9ER and COSMIC-313, which examined combination therapies in the frontline setting.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
